ACTON, Mass. — January 27, 2026 — Leads & Copy — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) has announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-4.
The reverse stock split will take effect at 12:01 a.m. Eastern Time on January 29, 2026. Trading on The Nasdaq Capital Market will begin on a post-split basis on January 29, 2026, under the trading symbol “BJDX.” The common stock will also commence trading with a new CUSIP number, 095633608.
At the effective time, every four shares of Bluejay common stock will be combined into one share of common stock, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 2,834,133 shares to approximately 708,533 shares. The number of shares of the Company’s common stock issuable upon the exercise of prefunded warrants will decrease from 1,055,000 to 263,750.
No fractional shares of common stock will be issued as a result of the reverse stock split. Holders of Bluejay common stock will receive a cash payment instead of fractional shares. The shares underlying the Company’s outstanding equity awards and warrants will be adjusted accordingly.
The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s common stock, except for adjustments that may result from the treatment of fractional shares.
Continental Stock Transfer & Trust Company (“Continental”) will act as the exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive instructions from Continental regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes.
Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.
Bluejay Diagnostics, Inc. is focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression.
Bluejay does not yet have regulatory clearance for the Symphony System and will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.
Source: Bluejay Diagnostics, Inc.
